Technical Analysis for GMDA - Gamida Cell Ltd.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 0.03 | -18.25% | -0.01 |
GMDA closed down 18.25 percent on Friday, April 5, 2024, on 2.02 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 7
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Calm After Storm | Range Contraction | -18.25% | |
NR7 | Range Contraction | -18.25% | |
NR7-2 | Range Contraction | -18.25% | |
Narrow Range Bar | Range Contraction | -18.25% | |
Inside Day | Range Contraction | -18.25% | |
Wide Bands | Range Expansion | -18.25% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Gamida Cell is a clinical stage biopharmaceutical company leveraging its proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The company is leveraging its nicotinamide-, or NAM-, based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Cyclacel Rare Serious Hematologic Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Pharmacy Cyclacel Rare Serious Hematologic Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
S
SociableGnat503 9 months ago
Any thoughts on this one? It's insane of how much this has bled over the past several weeks.
T
TraderMike 9 months ago
My only thoughts are this seems to be a small biotech doing what small biotechs do. These things are incredibly news driven, especially the clinical stage ones.
View full discussion...
Indicator | Value |
---|---|
52 Week High | 2.51 |
52 Week Low | 0.0303 |
Average Volume | 10,947,824 |
200-Day Moving Average | 0.76 |
50-Day Moving Average | 0.32 |
20-Day Moving Average | 0.24 |
10-Day Moving Average | 0.14 |
Average True Range | 0.04 |
RSI (14) | 22.48 |
ADX | 29.47 |
+DI | 15.02 |
-DI | 45.05 |
Chandelier Exit (Long, 3 ATRs) | 0.30 |
Chandelier Exit (Short, 3 ATRs) | 0.15 |
Upper Bollinger Bands | 0.55 |
Lower Bollinger Band | -0.06 |
Percent B (%b) | 0.15 |
BandWidth | 246.68 |
MACD Line | -0.09 |
MACD Signal Line | -0.06 |
MACD Histogram | -0.0302 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.04 | ||||
Resistance 3 (R3) | 0.04 | 0.04 | 0.04 | ||
Resistance 2 (R2) | 0.04 | 0.04 | 0.04 | 0.04 | |
Resistance 1 (R1) | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
Pivot Point | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
Support 1 (S1) | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 |
Support 2 (S2) | 0.03 | 0.03 | 0.03 | 0.02 | |
Support 3 (S3) | 0.02 | 0.03 | 0.02 | ||
Support 4 (S4) | 0.02 |